Hologic, Inc. $HOLX Shares Sold by QRG Capital Management Inc.

QRG Capital Management Inc. decreased its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 41.7% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 44,081 shares of the medical equipment provider's stock after selling 31,513 shares during the quarter. QRG Capital Management Inc.'s holdings in Hologic were worth $2,872,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of HOLX. Victory Capital Management Inc. increased its stake in Hologic by 34.4% during the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock valued at $408,283,000 after buying an additional 1,692,177 shares during the period. Nuance Investments LLC increased its stake in shares of Hologic by 623.7% during the first quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider's stock valued at $66,794,000 after acquiring an additional 931,920 shares during the period. Redwood Wealth Management Group LLC bought a new stake in Hologic during the first quarter worth approximately $3,534,000. Invesco Ltd. lifted its position in Hologic by 18.8% in the first quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock worth $298,655,000 after purchasing an additional 764,573 shares during the period. Finally, Nuveen LLC bought a new position in Hologic during the 1st quarter valued at $30,317,000. 94.73% of the stock is currently owned by institutional investors.

Insider Activity at Hologic

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the firm's stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the sale, the chief executive officer owned 1,234,624 shares of the company's stock, valued at $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 1.88% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently weighed in on HOLX. Evercore ISI upped their price objective on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a report on Tuesday, July 8th. Wall Street Zen cut shares of Hologic from a "buy" rating to a "hold" rating in a research report on Wednesday, October 1st. Morgan Stanley raised their price objective on shares of Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research report on Thursday, July 31st. Mizuho set a $75.00 target price on shares of Hologic in a report on Thursday, July 31st. Finally, Weiss Ratings restated a "hold (c-)" rating on shares of Hologic in a report on Saturday, September 27th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and nine have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $79.38.

Hologic Stock Performance

Shares of HOLX opened at $67.34 on Tuesday. The company has a 50-day moving average of $67.00 and a two-hundred day moving average of $63.15. The stock has a market cap of $14.98 billion, a price-to-earnings ratio of 27.94, a PEG ratio of 2.34 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the previous year, the business earned $1.06 earnings per share. The firm's revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.